BioPorto (CPSE:BIOPOR) - Stock Price, News & Analysis

BIOPOR Stock Overview

An in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. More details

BIOPOR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 31.66% per year

Risk Analysis

Earnings are forecast to decline by an average of 27.8% per year for the next 3 years

Does not have meaningful revenue (DKK35M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap (DKK698M)

+ 1 more risk

BioPorto A/S Competitors

Bavarian Nordic

CPSE:BAVA

DKK 15.6b

Genmab

CPSE:GMAB

DKK 94.2b

Oryzon Genomics

BME:ORY

€98.1m

Helixmith

KOSDAQ:A084990

₩138.6b

Price History & Performance

Summary of all time highs, changes and price drops for BioPorto
Historical stock prices
Current Share Price	DKK 1.62
52 Week High	DKK 3.85
52 Week Low	DKK 1.21
Beta	1.15
11 Month Change	-15.33%
3 Month Change	-22.11%
1 Year Change	-33.58%
33 Year Change	-48.53%
5 Year Change	-46.23%
Change since IPO	-99.29%

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

Oct 22

Recent updates

Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation

Oct 16

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

May 28

BioPorto A/S' (CPH:BIOPOR) Path To Profitability

Mar 01

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

Jan 24

A Look At BioPorto's (CPH:BIOPOR) CEO Remuneration

Dec 20

The BioPorto A/S (CPH:BIOPOR) Analysts Have Been Trimming Their Sales Forecasts

Nov 23

BioPorto A/S (CPH:BIOPOR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Nov 21

Shareholder Returns

	BIOPOR	DK Biotechs	DK Market
7D	-4.5%	3.1%	3.4%
1Y	-33.6%	-6.4%	7.5%

Return vs Industry: BIOPOR underperformed the Danish Biotechs industry which returned -6.4% over the past year.

Return vs Market: BIOPOR underperformed the Danish Market which returned 7.5% over the past year.

Price Volatility

Is BIOPOR's price volatile compared to industry and market?
BIOPOR volatility
BIOPOR Average Weekly Movement	5.7%
Biotechs Industry Average Movement	7.5%
Market Average Movement	4.2%
10% most volatile stocks in DK Market	10.5%
10% least volatile stocks in DK Market	2.5%

Stable Share Price: BIOPOR has not had significant price volatility in the past 3 months compared to the Danish market.

Volatility Over Time: BIOPOR's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1917	36	Peter Eriksen	bioporto.com

BioPorto A/S, an in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated clinical chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. BioPorto A/S was incorporated in 1917 and is based in Hellerup, Denmark.

BioPorto A/S Fundamentals Summary

How do BioPorto's earnings and revenue compare to its market cap?
BIOPOR fundamental statistics
Market cap	DKK 697.76m
Earnings (TTM)	-DKK 61.30m
Revenue (TTM)	DKK 34.91m

20.0x

P/S Ratio

-11.4x

P/E Ratio

Is BIOPOR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIOPOR income statement (TTM)
Revenue	DKK 34.91m
Cost of Revenue	DKK 10.05m
Gross Profit	DKK 24.86m
Other Expenses	DKK 86.16m
Earnings	-DKK 61.30m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.14
Gross Margin	71.22%
Net Profit Margin	-175.62%
Debt/Equity Ratio	0%

How did BIOPOR perform over the long term?

See historical performance and comparison

BIOPOR Stock Overview

Rewards

Risk Analysis

BioPorto A/S Competitors

CPSE:BAVA

DKK 15.6b

CPSE:GMAB

DKK 94.2b

BME:ORY

€98.1m

KOSDAQ:A084990

₩138.6b

Price History & Performance

Recent News & Updates

New minor risk - Market cap size

Bioporto A/S Maintains Revenue Guidance for the Year 2024

BioPorto A/S Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL) for Adult Use at Massachusetts General Hospital

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

Consensus EPS estimates fall by 80%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

New minor risk - Market cap size

Bioporto A/S Maintains Revenue Guidance for the Year 2024

BioPorto A/S Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL) for Adult Use at Massachusetts General Hospital

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

Consensus EPS estimates fall by 80%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bioporto A/S Affirms Earnings Guidance for 2024

New major risk - Share price stability

New minor risk - Shareholder dilution

BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024

Bioporto A/S Provides Revenue Guidance for 2024

First quarter 2024 earnings released: kr.0.04 loss per share (vs kr.0.048 loss in 1Q 2023)

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

BioPorto A/S Announces CEO Changes

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

BioPorto A/S to Report Nine Months, 2024 Results on Oct 30, 2024

BioPorto A/S, Annual General Meeting, Apr 30, 2024

New major risk - Share price stability

BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Consensus estimates of losses per share improve by 16%

New major risk - Financial position

Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023

Bioporto A/S Announces Resignation of Neil Goldman as CFO

BioPorto A/S announced that it has received $0.11 million in funding

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

BioPorto A/S Maintains Earnings Guidance for the Year 2023

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

New minor risk - Shareholder dilution

High number of new and inexperienced directors

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

BioPorto A/S Maintains Financial Guidance for 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

BioPorto A/S, Annual General Meeting, Apr 27, 2023

BioPorto A/S Appoints Nis Kruse as EVP of Strategic Partnerships and Gm of EMEA & Apac

Less than half of directors are independent

BioPorto A/S Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

BioPorto A/S Revises Earnings Guidance for the Year 2022

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

BioPorto A/S Revises Earnings Guidance for the Year 2022

Second quarter 2022 earnings: Revenues exceed analyst expectations

BioPorto A/S Revises Earnings Guidance for the Year 2022

BioPorto A/S Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S

BioPorto A/S Appoints Dr. Prasad Devarajan as New Senior Medical Director

We're Keeping An Eye On BioPorto's (CPH:BIOPOR) Cash Burn Rate

BioPorto A/S Maintains its Earnings Guidance for the Year 2022

Price target decreased to kr.3.50

Less than half of directors are independent

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

BioPorto A/S Provides Earnings Guidance for the Full Year 2022

Is BioPorto (CPH:BIOPOR) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Third quarter 2021 earnings released: kr.0.04 loss per share (vs kr.0.087 loss in 3Q 2020)

Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation

Second quarter 2021 earnings released: kr.0.051 loss per share (vs kr.0.077 loss in 2Q 2020)